About celularity inc. - CELU
Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert Joseph Hariri Gordon in 2016 and is headquartered in Florham Park, NJ.
CELU At a Glance
Celularity, Inc.
170 Park Avenue
Florham Park, New Jersey 07932
| Phone | 1-908-768-2170 | Revenue | 54.22M | |
| Industry | Miscellaneous Commercial Services | Net Income | -57,892,000.00 | |
| Sector | Commercial Services | 2024 Sales Growth | 138.11% | |
| Fiscal Year-end | 12 / 2025 | Employees | 123 | |
| View SEC Filings |
CELU Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.84 |
| Price to Book Ratio | 5.307 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.71 |
| Enterprise Value to Sales | 2.096 |
| Total Debt to Enterprise Value | 0.606 |
CELU Efficiency
| Revenue/Employee | 440,813.008 |
| Income Per Employee | -470,666.667 |
| Receivables Turnover | 3.999 |
| Total Asset Turnover | 0.237 |
CELU Liquidity
| Current Ratio | 0.383 |
| Quick Ratio | 0.282 |
| Cash Ratio | 0.014 |
CELU Profitability
| Gross Margin | 57.744 |
| Operating Margin | -71.101 |
| Pretax Margin | -106.772 |
| Net Margin | -106.772 |
| Return on Assets | -25.282 |
| Return on Equity | -232.512 |
| Return on Total Capital | -74.533 |
| Return on Invested Capital | -83.629 |
CELU Capital Structure
| Total Debt to Total Equity | 778.952 |
| Total Debt to Total Capital | 88.623 |
| Total Debt to Total Assets | 21.916 |
| Long-Term Debt to Equity | 706.971 |
| Long-Term Debt to Total Capital | 80.433 |